NEW YORK (GenomeWeb News) – French genome engineering company Cellectis said yesterday that that the European Patent Office has upheld one of its patents that has been the subject of ongoing litigation with US biotech firm Precision BioSciences.

However, in a statement released this morning, Precision BioSciences said that the EPO had "severely restricted" Cellectis' claims under the patent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.